Detail akcie Zymeworks Rg online

Business Summary: Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Zymeworks Inc revenues increased from $45.3M to $103.5M. Net loss decreased 60% to $39.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects discovery, development and commercialization segment loss decrease of 58% to $48.4M.